REG - Polarean Imaging PLC - Dr. Bastiaan Driehuys awarded by ATS

Polarean ImagingAnnouncement

21/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250521:nRSU4631Ja&default-theme=true

RNS Number : 4631J  Polarean Imaging PLC  21 May 2025

 

Polarean Imaging plc

("Polarean" or the "Company")

 

American Thoracic Society honours Dr. Bastiaan Driehuys for pioneering work in
Xenon MRI

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging
technology leader in advanced Magnetic Resonance Imaging ("MRI") of lung
function, announces that Bastiaan Driehuys, PhD, has received a 2025 American
Thoracic Society ("ATS") Respiratory Health Award for his translational work
in bringing Xenon MRI from the bench to the clinic. Dr. Driehuys has been
presented with ATS's Research Innovation and Translation Achievement
Award for his exemplary accomplishments in respiratory health based on his
work at Duke University Medical Center.

 

Dr. Driehuys invented hyperpolarised gas MRI while completing his Doctorate in
Atomic Physics at Princeton University, and co-founded Polarean. He and his
team developed the underlying technology of Xenon-129 hyperpolarisation, as
well as novel MR image acquisition, reconstruction, and analysis strategies
and how to apply them to problems in pulmonary medicine. He currently holds
the position of Chief Scientific Officer at Polarean. Much of Dr. Driehuys'
work resulted in the core Xenon MRI technology being commercialised by
Polarean. His later work on utilising Xenon MRI for the study of gas exchange
and cardiopulmonary indications while at Duke are exclusively licensed to
Polarean.

 

Bastiaan Driehuys, PhD, Chief Scientific Officer of Polarean said: "I am
deeply honoured to receive the 2025 Research Innovation and Translation
Achievement Award. This recognition reflects the dedication of an incredible
community of interdisciplinary scientists and physicians who have advanced
Xenon MRI into a transformative tool for 3D assessment of pulmonary function.
I'm excited to continue working with my ATS colleagues to bring this
technology to bear on improving the care of patients worldwide."

 

Christopher von Jako, PhD, CEO of Polarean, added: "We were delighted to learn
that Dr. Driehuys has been recognised by the American Thoracic Society for his
groundbreaking contributions to pulmonary imaging. His work is not only
advancing the science-it is directly benefiting patients by enabling earlier
detection, improved treatment planning, and better outcomes for those with
serious respiratory conditions. Bastiaan is a vital part of our team at
Polarean, and we are proud to see his impact acknowledged with such a
prestigious award. Honours like this reflect the highest standards in science
and clinical care, and we look forward to continuing to build on his expertise
to transform respiratory health."

 

Enquiries:

 

 Polarean Imaging plc                                              www.polarean.com / www.polarean-ir.com (http://www.polarean-ir.com)
 Christopher von Jako, Ph.D., Chief Executive Officer              Via Walbrook PR
 Charles Osborne, Chief Financial Officer

 Stifel (NOMAD and Sole Corporate Broker)                                                   +44 (0)20 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Walbrook PR            Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy / Paul McManus / Marcus Ulker

 

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform. For the latest news and information about Polarean,
please visit www.polarean.com (http://www.polarean.com/) .

 

XENOVIEW IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW®, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 12 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.
XENOVIEW is currently not approved for use in pediatric patients less than 12
years of age.

 

Please see full prescribing information at www.XENOVIEW.net
(http://www.XENOVIEW.net)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBUGDUBGDDGUG